Vivani Medical Stock Price, News & Analysis

Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn will present at the 2025 BIO International Convention in Boston on June 18, 2025. The presentation will showcase Vivani's NanoPortal™ drug implant technology, which focuses on developing miniature, ultra long-acting drug implants to improve medication adherence in chronic disease management. The company's leading product, NPM-115, is a six-month GLP-1 implant using exenatide for chronic weight management in obese or overweight individuals. Results from their first human clinical trial, LIBERATE-1™, are anticipated later in 2025.

Vivani Medical (NASDAQ: VANI) has announced plans to spin off its neurostimulation subsidiary, Cortigent, as an independent Nasdaq-listed company in Q3 2025. Cortigent has filed a Form 10 registration statement with the SEC for this purpose. The spin-off will create two focused companies: Cortigent will develop brain implant devices, including the Orion® Visual Cortical Prosthesis System for the blind and the Stroke Recovery System for post-stroke paralysis recovery. Vivani will focus on developing NanoPortal™ drug implants, specifically GLP-1 implants for weight management and type 2 diabetes. Cortigent's Orion system has FDA Breakthrough Device designation and completed a six-year Early Feasibility Study in March 2025. The transaction aims to provide investors with greater visibility into each company's operations and create long-term value through dedicated management teams and focused strategic priorities.

Vivani Medical (NASDAQ: VANI) reported Q1 2025 financial results and secured additional funding through equity financing. The company raised $3M at $1.03 per share, following an earlier $8.25M raise at $1.12 per share, extending their financial runway into mid-2026. Their LIBERATE-1™ study, testing NPM-115 (exenatide implant) in obese/overweight individuals, achieved successful implant insertions with top-line results expected mid-2025. Vivani released promising pre-clinical data for NPM-139 (semaglutide implant) and expanded their collaboration with Okava Pharmaceuticals to include dogs. The company plans to spin off Cortigent, Inc., their brain implant division, as a separate public company. Q1 2025 financials show a cash balance of $14.3M, with a net loss of $6.3M compared to $6.0M in Q1 2024. R&D expenses increased 13% to $4.2M, while G&A expenses decreased 6% to $2.3M.

Vivani Medical (NASDAQ: VANI) announced its CEO Adam Mendelsohn's upcoming participation in the American Association of Pharmaceutical Scientists' virtual workshop "Beyond GLP1s: Where the Science will Take Business Next" on May 13-14, 2025. Dr. Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" on May 14 at 11:15 am ET, focusing on Vivani's miniature drug implants and their proprietary NanoPortal™ technology.

The company's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant for weight management, with results from the LIBERATE-1™ human study expected this year. Dr. Mendelsohn will also participate in a panel discussion at 2:00 pm ET about key hurdles and trends in GLP-1 drug class development.

Vivani Medical (NASDAQ: VANI) has announced its participation in a virtual fireside chat hosted by H.C. Wainwright & Company on April 24, 2025, at 10 a.m. Eastern Time. The presentation will feature CEO Adam Mendelsohn, Ph.D., and CMO Lisa Porter, M.D., who will discuss the company's LIBERATE-1 clinical trial.

The discussion will focus on NPM-115, Vivani's innovative miniature, twice-yearly GLP-1 (exenatide) implant being developed for chronic weight management. The company is currently conducting LIBERATE-1 as a first-in-human study, with topline data expected in mid-year 2025.

Vivani specializes in developing miniature, ultra long-acting drug implants, with a portfolio focusing on once or twice-yearly GLP-1 implants for both chronic weight management and type 2 diabetes treatment.

Vivani Medical (NASDAQ: VANI) and Okava Pharmaceuticals have expanded their collaboration to develop OKV-119, a long-acting GLP-1 therapy for dogs, targeting weight management, diabetes, and cardiometabolic conditions. The therapy utilizes Vivani's NanoPortal™ technology to deliver therapeutic molecules over extended periods from a single implant.

The collaboration, initially focused on cats since 2019, now addresses a critical need as over 50% of U.S. dogs are overweight or obese. OKV-119 aims to provide dosing every six months or longer, mimicking the physiological effects of fasting without disrupting feeding routines. Research indicates leaner dogs can live more than two years longer than heavier ones.

The expanded partnership maintains minimal costs and risks for Vivani while offering potential upside through future milestone payments and royalties. The financial terms of the agreement were not disclosed.

Vivani Medical (NASDAQ: VANI) reported its Q4 and full year 2024 results, highlighting significant progress in its drug implant programs. The company successfully completed enrollment in its LIBERATE-1™ first-in-human study of NPM-115 (exenatide implant), with top-line data expected in mid-2025.

Key developments include positive preclinical weight loss data for NPM-139 (semaglutide implant), showing comparable results to Ozempic®/Wegovy® injections with potential for once-yearly dosing. The company secured $8.25M in equity financing, extending operations into Q2 2026.

Financial highlights for 2024:

• Cash position: $19.7M as of December 31, 2024
• Net loss: $23.5M, improved from $25.7M in 2023
• R&D expenses: $15.7M, down 7% from 2023
• G&A expenses: $8.9M, decreased 11% from 2023

The company plans to spin off its Cortigent subsidiary, which develops brain implant devices, to focus on its drug implant pipeline for chronic diseases.

Vivani Medical (NASDAQ: VANI) has secured an $8.25 million private placement equity financing through the sale of 7,366,071 shares at $1.12 per share. The financing was arranged with an entity owned by Gregg Williams, the Company's board chairman.

The funding will extend the company's cash runway into Q2 2026 and accelerate the development of two key products:

• NPM-139: A once or twice-yearly GLP-1 (semaglutide) implant for chronic weight management
• NPM-115: A twice-yearly GLP-1 (exenatide) implant for chronic weight management

The private placement was priced 'at-the-market' under Nasdaq rules and will have multiple closing dates. The securities being sold have not been registered under the Securities Act of 1933.

Vivani Medical (NASDAQ: VANI) has announced promising preclinical data for NPM-139, its subdermal semaglutide implant for chronic weight management. The implant, utilizing their proprietary NanoPortal™ technology, demonstrated nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over a 91-day treatment period.

The technology successfully delivers semaglutide (active ingredient in Ozempic®/Wegovy®) with potential for once or twice-yearly dosing. NPM-139 has shown therapeutic semaglutide exposure levels over six months in healthy rats, with in vitro stability measurements indicating potential for once-yearly administration.

The company's ongoing LIBERATE-1 clinical study for NPM-115 (exenatide implant) is progressing, with top-line data expected by mid-2025. This study will provide critical information for both NPM-115 and NPM-139 development, representing the first human application of NanoPortal technology.